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Article
New and emerging technologies
for the diagnosis and monitoring
of chronic obstructive pulmonary
disease: A horizon scanning review
Louise C Dixon1, Derek J Ward1, Joanna Smith1,
Steve Holmes2 and Ravi Mahadeva3
Abstract
There is a need for straightforward, novel diagnostic and monitoring technologies to enable the early diagnosis
of COPD and its differentiation from other respiratory diseases, to establish the cause of acute exacerbations
and to monitor disease progression. We sought to establish whether technologies already in development
could potentially address these needs. A systematic horizon scanning review was undertaken to identify
technologies in development from a wide range of commercial and non-commercial sources. Technologies
were restricted to those likely to be available within 18 months, and then evaluated for degree of innovation,
potential for impact, acceptability to users and likelihood of adoption by clinicians and patients with COPD.
Eighty technologies were identified, of which 25 were considered particularly promising. Biomarker tests,
particularly those using sputum or saliva samples and/or available at the point of care, were positively evaluated,
with many offering novel approaches to early diagnosis and to determining the cause for acute exacerbations.
Several wrist-worn devices and smartphone-based spirometers offering the facility for self-monitoring and
early detection of exacerbations were also considered promising. The most promising identified technologies
have the potential to improve COPD care and patient outcomes. Further research and evaluation activities
should be focused on these technologies.
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Introduction
Chronic obstructive pulmonary disease (COPD) is the
third leading cause of death globally and presents a
significant burden to patients, carers and health ser-
vices worldwide.1,2 More than 1.5 million adults are
known to be diagnosed with COPD in England and
Wales, and a further 3 million adults are estimated to
be living with undiagnosed COPD.3,4 Improving the
care and outcomes for people with COPD is a priority
for the National Health Service (NHS) in England,
which aims to reduce premature mortality from
respiratory disease, avoid unnecessary hospital
admissions and improve the quality of life and support
for patients with long-term conditions and their
carers.5 However, several current issues remain in the
diagnosis and monitoring of COPD, some of which
could be resolved by technological developments or
novel disease biomarkers.
Several authors have noted limitations in the use
of spirometry to diagnose COPD due to differing
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guidelines as to what constitutes COPD, difficulties in
technique encountered by frail or cognitively
impaired patients, and a lack of awareness and knowl-
edge in primary care leading to delayed diagnosis,
especially in non-smoking subgroups.6–9 In addition,
some commentators have proposed a need for
improved diagnostic criteria where asthma and COPD
coexist, observing that non-specialist clinicians fre-
quently find it difficult to both diagnose and manage
this situation,8,10,11 whilst others consider that addi-
tional emphasis should be placed on early detec-
tion.9,12,13 There is an unmet need for simple,
accurate testing approaches that would enable early
diagnosis and differentiation from other respiratory
diseases.13 As part of the ongoing care of COPD,
patient self-monitoring is increasingly being recog-
nized as beneficial, with evidence indicating this may
improve health-related quality of life and the recog-
nition and management of acute exacerbations,14,15
and self-monitoring is recommended in guidelines
from the National Institute for Health and Care Excel-
lence (NICE).2 However, the most effective approach
to self-management in COPD is not known.14 Finally,
several commentators identify the need to determine
the cause of acute exacerbations as a research need;
this would allow treatment to be tailored to the under-
lying pathology.16,17 Correspondingly the NICE
Database of Uncertainties about the Effects of Treat-
ments includes questions about the appropriate use of
corticosteroids and antibiotics for the management of
acute exacerbations of COPD.18,19 As only around
half of exacerbations are associated with a bacterial
infection and a only a third of exacerbations demon-
strate eosinophilic inflammation, the use of these
agents may expose many patients to significant
adverse effects and the potential development of anti-
biotic resistance for no apparent benefit.20,21 There is
an unmet need for novel diagnostic or monitoring
approaches, particularly those available at the point
of care, to establish the cause of acute exacerbations
and to monitor the progression of the disease.
Horizon scanning systems, or early awareness and
alert systems, aim to identify significant health tech-
nologies prior to launch that may require further
assessment or planning prior to adoption.22,23 A hor-
izon scanning review uses systematic methods to
identify, filter, prioritize and present early informa-
tion on all new and emerging technologies relevant to
the area of interest, however, it does not assess the
evidence supporting the identified technologies, vali-
date the claims made about them by developers or
comprehensively evaluate the potential impact they
may have on clinical care.24,25 We sought to identify
new and emerging technologies already in develop-
ment for the diagnosis or monitoring of COPD that
could potentially address the unmet research and clin-
ical practice needs identified above, and then use the
views of clinical experts and patients with COPD to
establish which of these technologies could be con-
sidered the most innovative, acceptable and likely to
make an impact on patients and health services in the
future. This horizon scanning review forms part of the
National Institute for Health Research Horizon Scan-
ning Research and Intelligence Centre work pro-
gramme. The full report is available on the Centre’s
website (http://www.hsric.nihr.ac.uk/news/what-
does-the-future-hold-for-copd-diagnostic-and-moni-
toring-technologies/) and will be used to inform
healthcare policymakers, commissioners, researchers,
research funders, clinicians and patients about new
technologies ‘on the horizon’ for the management of
COPD. Ethical approval was obtained from the Uni-
versity of Birmingham’s Internal Ethical Review
Committee (reference: IERC2014-5/C1/SF/07).
Methods
Identification and filtration of technologies
Between January and March 2015, potential technol-
ogies for the diagnosis and monitoring of COPD were
identified by searching relevant online databases and
other websites (Table 1) using pre-specified search
terms (Table 2) and eliciting suggestions from clinical
experts. Initial search findings were filtered to include
only those technologies which were new (already
licensed/CE marked or launched in the United
Kingdom for 24 months – in the launch, early
post-marketing or early diffusion phase) or emerging
(in development and expected to be licensed/CE
marked in the next 18 months – in late phase clinical
trials, prelaunch or pre-marketing phase), and results
were further prioritized to include only those technol-
ogies that demonstrated, or claimed to demonstrate,
some degree of innovation (either a completely novel
technology, with no direct comparators already mar-
keted, or a significant development from existing
marketed products).
External input
Clinical experts and patients with COPD were
recruited as expert external advisors to the review.
2 Chronic Respiratory Disease
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Table 1. Search protocol – pre-specified identification sources.
Source name Website link
Published medical literature
Medline & Medline in Progress, & EMBASE Accessed via http://www.elibrary.bham.ac.uk/
PubMed.gov http://www.ncbi.nlm.nih.gov/pubmed
The Cochrane Library http://www.cochranelibrary.com/
ZETOC British Library Database http://zetoc.mimas.ac.uk/
HTA agencies
AHRQ Healthcare Horizon Scanning System Status update reports and potential high impact reports via http://
www.effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-
reports/?pageaction¼displayproduct&productid¼881
CADTH http://www.cadth.ca
ECRI Institute http://www.ecri.org
EuroScan International Network http://euroscan.org.uk/
NIHR Horizon Scanning Research &
Intelligence Centre database
http://www.hsric.nihr.ac.uk/
Clinical trial registries and research funding databases
ClinicalTrials.gov http://clinicaltrials.gov/
COPD clinical research network http://www.copdcrn.org/
Current-controlled trials http://www.controlled-trials.com/
MRC-funded research http://www.mrc.ac.uk/research/funded-research/
NIHR Biomedical Research Centres and
Units annual dataset (2014)
Not applicable
NIHR Evaluation Trials and Studies Project
portfolio
http://www.nets.nihr.ac.uk/
projects?collection¼netscc&meta_P_sand¼Project
UKCRN portfolio database http://public.ukcrn.org.uk/search/
World Health Organization International
Clinical Trials Registry Platform
http://www.who.int/ictrp/en/
Specialist media and commercial research and development databases
AdvamedSmartbrief https://www2.smartbrief.com/news/ADVAMED/index.jsp
Clinica http://www.clinica.co.uk/
Fierce Devices http://www.fiercemedicaldevices.com/
GlobalData Medical http://globaldata.com/medical/Login.aspx?ReturnUrl¼%2fmedical
MedGadget http://www.medgadget.com/
Medical News Today http://www.medicalnewstoday.com/
Regulatory authorities
USFDA approvals http://www.fda.gov/newsevents/productsapprovals/default.htm
Specialist journals
American Journal of Respiratory and Critical
Care Medicine
http://www.atsjournals.org/journal/ajrccm
COPD: Journal of Chronic Pulmonary
Obstructive Disease
http://informahealthcare.com/loi/cop
European Respiratory Journal http://erj.ersjournals.com/
Expert Reviews of Respiratory Medicine http://informahealthcare.com/loi/erx
International Journal of Chronic Obstructive
Pulmonary Disease
http://www.dovepress.com/international-journal-of-chronic-obstructive-
pulmonary-disease-journal
Thorax http://thorax.bmj.com/
Professional and patient groups
American Thoracic Society http://www.thoracic.org/
British Lung Foundation http://www.blf.org.uk/Home
British Thoracic Society https://www.brit-thoracic.org.uk/
COPD Foundation http://www.copdfoundation.org/
European Lung foundation http://www.europeanlung.org/en/
European Respiratory Society http://www.ersnet.org/
Primary Care Respiratory Society http://www.pcrs-uk.org/
Royal College of Physicians https://www.rcplondon.ac.uk/
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Clinical experts were identified from initial scoping
and literature searches and the NICE COPD guideline
development and review panel. Fifteen clinical
experts were contacted via email and asked to act as
review advisors, five of whom subsequently agreed,
resulting in an expert panel comprising consultant
respiratory physicians, a general practitioner with a
special interest in respiratory disease and a clinical
nurse specialist. Clinical experts were emailed the
table of identified technologies and asked to provide
their views on each technology’s level of innovation,
potential for impact (on patients and the delivery of
health services), potential barriers to adoption and any
further comments. They were also asked to identify
any additional relevant technologies or relevant
research they were aware of that had not already been
identified.
Patients with COPD were identified from the
patient advisory group to the existing Birmingham
Lung Improvement StudieS (BLISS) research pro-
gramme.26 Members of the group were approached
using a standard email or letter informing them of the
review and inviting them to participate. Three patients
subsequently agreed and were sent the table of iden-
tified technologies and asked to provide their views
on each technology’s level of innovation, potential for
impact (on patients and the delivery of health ser-
vices) and acceptability to users, along with any fur-
ther comments.
Review output
All identified new and emerging technologies for the
diagnosis or monitoring of COPD were included in
the final report. Clinical expert and patient views were
used to identify those technologies that were consi-
dered to demonstrate a high degree of innovation
and/or a significant potential for impact and adoption
by the NHS in England.
Results
Eighty new and emerging technologies for the diagnosis
and monitoring of COPD were identified (Table 3,
Figure 1). These included 31 biomarkers, 21 telehealth
technologies, 6 wearable technologies, 6 imaging tech-
nologies, 4 vital sign monitors, 4 questionnaires, 3 spi-
rometers and 5 additional other technologies. Clinical
experts and patients provided comments on all identi-
fied technologies, providing useful insights into the
innovativeness, potential impact, stage of development
and probable timeframe for each technology. Of the
technologies identified, 25 (31.3%) were considered
particularly promising, demonstrating a high degree of
innovation and with a significant potential for impact
and adoption by the NHS according to expert and
patient comments (Table 4).
Wearable technologies
All identified wearable technologies were intended to
monitor stable COPD through devices worn either
across the chest or on the wrist. Whilst devices mon-
itoring respiratory rate, wheeze, blood oxygenation
and/or temperature are already available, several new
technologies enabled self-monitoring at home with
remote access by clinicians, though the feasibility of
multiple clinicians interpreting large volumes of
recorded data was questioned. Patients commented
that users may be unwilling to wear a ‘cumbersome’
looking device and were concerned about ‘having the
restriction of a band around [their] chest’. The wrist-
based pulse oximeter and BuddyWOTCH devices
could offer alternatives to existing fingertip devices,
providing continuous monitoring without limiting
movement of the user’s hands. In addition, Buddy-
WOTCH captures physical activity, temperature and
heart rate. Both technologies were considered promis-
ing, with patients keen to try a more compact, watch
style device. Experts considered them ‘potentially
useful . . . for longer term monitoring . . . in vulnerable
groups . . . [and] for pulmonary rehabilitation’.
Table 2. Search protocol – pre-specified search terms.
Condition and
synonyms
Chronic obstructive pulmonary disease
COPD
Chronic obstructive airways disease
COAD
Chronic obstructive lung disease
Chronic obstructive respiratory disease
Chronic airflow limitation
Emphysema
Chronic bronchitis
Diagnosis Diagnosis
Recognition
Detection
Identification
Test
Point-of-care test
Monitoring Monitoring
Surveillance
Review
Timeframe New
Emerging
4 Chronic Respiratory Disease
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Concerns were expressed regarding the reliability of
wrist-based monitoring; however, a potentially large
impact could be expected if these devices demon-
strated acceptable performance.
Biomarker technologies
Thirty-one biomarker tests were identified and
included in the report, the majority based on blood
samples. Alternative samples included sputum, bron-
chial aspirate and innovatively, saliva and volatile
organic compounds from breath samples. Most bio-
markers were intended for the diagnosis of COPD, but
experts dismissed the majority of blood-based diag-
nostic biomarkers as being too early in development
or ‘possibly as a research tool’ with no demonstrated
clinical value, despite some being considered highly
innovative. Aa-Val360 was the most promising bio-
marker in this category, having been proposed as a
method to identify patients with early COPD at risk of
progression. Experts commented that it was ‘highly
innovative . . . targeting high risk individuals’. Fourier
transform infrared spectroscopic monitoring used
sputum to rapidly differentiate COPD from other
respiratory conditions and determine the risk of an
imminent exacerbation; experts commented that this
was ‘interesting and if effective then impact and
adoption [are] possibly significant’. A further
sputum-based biomarker panel to diagnose asthma-
COPD overlap was thought to be ‘of interest in sec-
ondary care clinics’, whilst experts considered
COPD-saliva point of care (SPOC), a novel saliva-
based point-of-care test for the diagnosis of COPD
incorporating three biomarkers, to have the ‘potential
to change practice’.
Several inflammatory blood biomarkers were pro-
posed for the monitoring of COPD for risk of an acute
exacerbation. However, fibrinogen and C-reactive
protein (CRP) were noted to be ‘non-specific indica-
tors of inflammation’ and therefore ‘unlikely to be
much impact or . . . [high adoption]’. In contrast, pro-
calcitonin was thought to be a ‘more specific marker
of infection’. Researchers claimed it was able to dif-
ferentiate between a bacterial and nonbacterial cause
of acute exacerbations, prompting an expert to state
‘ . . . a strong chance of high impact (more appropriate
exposure to antibiotics) and adoption’. The Home Use
Sputum Test may provide advance warning of an
acute exacerbation in the community and experts
were very positive, commenting ‘this would be useful
and may help identify pathogens early so treatment
can be commenced’, and highlighting the potential to
‘reduce antibiotic use’, though also noting ‘identify-
ing a bacterium does not always mean that the cause
of symptoms is identified’. Patients commented on its
potential to ‘reassure patients’. Other technologies
aimed to identify the cause of acute exacerbations in
order to better direct specific management. Experts
commented that the use of peripheral blood eosino-
phil count as a biomarker to direct corticosteroid
Table 4. Promising technologies – those considered to
demonstrate a high degree of innovation, potential for
impact, and potential for adoption by the NHS.
Technology type Promising technologies
Wearable technologies Wrist-based pulse oximeter
BuddyWOTCH
Biomarker technologies
Diagnostic Aa-Val 360 biomarker
Biomarker panel: SP-A,
sRAGE, MPO and NGAL
for asthma-COPD
overlap syndrome
FTIR monitoring
COPD-SPOC sensor
Monitoring Home use sputum test
To determine the cause
of an acute exacerbation
Blood eosinophil biomarker
CRP point-of-care test
PCT
Telehealth technologies Virtual Medical Assistant
Version 2.0
Commander Flex
MedVizer T400 Home
Health Monitor
ADAPT
SmartScope System
Respiratory virtual clinics
Spirometry technologies MySpi-roo
MIR Smart One1
Smartphone spirometer
Questionnaire technologies DECAF scoring system
DOSE index
Other technologies SPPB
ResPOC point-of-care
testing for respiratory
viruses
HIRA-TAN semi-
quantitative PCR
mPCR
FTIR: Fourier transform infrared; SPOC: saliva point of care;
COPD: chronic obstructive pulmonary disease; DOSE: dyspnoea,
obstruction, smoking, exacerbation; mPCR: multiplex polymerase
chain reaction; ADAPT: After DischArge Pulmonary Telehealth;
CRP: CRP: C-reactive protein; ResPOC: Respiratory Virus Point-
Of-Care; DECAF: Dyspnoea, Eosinopenia, Consolidation, Acidae-
mia and atrial Fibrillation.
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therapy was ‘worth exploring more’, though impact
was judged to be ‘unclear, as most exacerbations are
in the community and [this biomarker] will need a
blood test’. The CRP POC test was considered inno-
vative, providing an accessible fingerprick test in
community settings. One expert remarked ‘yes to
innovation, yes to potential impact and adoption is a
strong possibility if shown to help decision making’.
Telehealth technologies
Telehealth is a popular area of development in tech-
nologies for chronic diseases and represented a large
proportion of all technologies identified. Many
devices were in a late stage of development from
established commercial developers and had already
obtained a CE mark, making them more likely to
come to market within the specified timeframe. How-
ever, telehealth was generally viewed negatively by
the clinical experts, with comments aimed at the cate-
gory as a whole rather than in-depth review of each
technology. Experts cited a UK multicentre trial of
touchscreen telemonitoring for COPD27 and a sys-
tematic review and meta-analysis of telehealth for
COPD,28 commenting on the current high estimates
for cost-effectiveness of similar technologies and the
lack of evidence that they improve quality of life or
reduce mortality. In addition, experts expressed
Search hits
(n = 4171) 
Non-relevant hits 
(n = 4031) 
Technologies identified 
(n = 140) 
Duplicates removed 
(n = 12) 
Technologies filtered 
(n = 128) 
Technologies excluded 
(n = 36) 
Technologies prioritised 
(n = 92) 
Technologies excluded 
(n = 12) 
Technologies assessed 
(n = 80) 
Additional technologies 
identified by clinical experts 
(n = 0) 
Technologies included in the 
final report 
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Figure 1. Identification, filtration and prioritization of technologies included in the horizon scanning review. Adapted
from the PRISMA flow diagram for systematic reviews.30
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concern about the burden on clinicians, saying ‘the
problem with this kind of technology is that you need
a healthcare professional to look at the data’.
Imaging technologies
The majority of imaging technologies were consid-
ered highly innovative, but clinical experts believed
their use would be restricted to research or specialist
centres, so that uptake was likely to be very limited,
and these technologies had little potential for impact
across the whole of the NHS.
Vital sign monitoring technologies
Four devices offered novel methods for monitoring
COPD. Both EverOn and the Respiratory Holter tech-
nologies monitored respiratory rate, with one expert
noting ‘the accurate long-term measurement of
respiratory rate in hospital/home may be useful’.
However, neither were particularly novel and experts
were unsure whether they would be ‘useful in the real
world’. Similarly, Capno-Pulse received mixed com-
ments from experts, with some identifying a role for
improved non-invasive arterial blood carbon dioxide
monitoring and others unclear whether it had potential
for impact. However, patients were generally more
positive, saying they would be willing to try these
devices.
Spirometry technologies
These devices use a smartphone mounted, handheld
device for home monitoring of COPD. Most clini-
cians are aware that monitoring current spirometric
parameters does not reliably detect deterioration or
exacerbation in COPD, though changes may be evi-
dent in asthma and potentially asthma-COPD over-
lap.2 However, comments were mostly encouraging,
with good potential for adoption when used in con-
junction with training and appropriate follow-up.
Patients considered these technologies ‘could have
[a] considerable impact’ and were ‘definitely’ accep-
table to users. Two devices incorporate Bluetooth
technology, however, the additional impact of this
connectivity was thought to be limited due to the
requirement for an interpreting clinician and patients’
ability to respond to the results.
Questionnaire-based technologies
Questionnaires were considered acceptable by
patients providing they were not too long as ‘patients
do get tired of filling in forms’. Two questionnaires
aimed to monitor the severity of exacerbations in
order to inform clinical decisions regarding care. The
Dyspnoea, Eosinopenia, Consolidation, Acidaemia
and atrial Fibrillation (DECAF) score was considered
a ‘useful innovation to predict safe early discharge’,
whilst experts disagreed about the Dyspnoea,
Obstruction, Smoking, Exacerbation (DOSE) index,
with one noting that it is ‘well validated . . . difficult
to see why not used more’ and another commenting
‘not clear to me that it is any advance over existing
risk assessment tools’. Two questionnaires were
aimed at COPD diagnosis. The COPD screening
questionnaire includes smoking history and symp-
toms and aims to facilitate early diagnosis. Again,
experts were divided in their opinions. One commen-
ted it was ‘a useful way to identify and encourage
people to get spirometry’ whereas another said it was
‘not novel, tools already exist’.
Other technologies
Three technologies aimed to diagnose the cause of
acute exacerbations in order to direct treatment. The
developer of Respiratory Virus Point-Of-Care
(ResPOC), a point-of-care test, claims it is capable
of identifying respiratory viruses within 1 hour, with
an equivalent accuracy to that of standard laboratory
tests. Multiplex-polymerase chain reaction uses sim-
ilar technology to diagnose viral infections using sam-
ples of tracheal or nasal aspirate, whilst HIRA-TAN
may provide rapid and sensitive identification of bac-
terial pathogens. All of these three similar technolo-
gies received positive comments from experts, noting
they were ‘innovative’ with high ‘potential for impact
and adoption’.
Discussion
We identified a large number of new and emerging
technologies for the diagnosis and monitoring of
COPD, almost a third of which were considered to
be innovative with significant potential for impact
on patients and health services and be appropriate for
adoption by the NHS. The technologies included in
this horizon scanning review broadly addressed the
issues identified as key research and unmet practice
needs. Novel biomarkers offered a potential future
alternative approach to early diagnosis and the differ-
entiation from other respiratory diseases, including
several based on sputum or saliva samples with results
available at the point of care. Experts were less
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favourable about non-COPD-specific biomarkers of
inflammation, though plasma fibrinogen has since
become the first COPD biomarker to receive Food
and Drug Administration approval for use in interven-
tional clinical trials.29 Many technologies offered
the potential to facilitate patient self-monitoring,
including vital sign monitors (including wearable
technologies), telehealth systems, smartphone-based
spirometers and biomarkers, with a home-use sputum
test potentially allowing advance warning of an acute
exacerbation. Patients emphasized their preference
for compact, simple, easy to use and portable moni-
toring devices that did not interfere with daily life, so
that wrist-worn devices were preferred over vest-like
wearable devices. Importantly, six innovative tech-
nologies were identified with the potential to establish
the cause of an acute exacerbation, two of which
offered this as at the point of care. These could enable
treatment of acute exacerbations to be tailored to the
underlying pathology, potentially avoiding the unne-
cessary use of antibiotics and corticosteroids.
The review used an established horizon scanning
review methodology to systematically identify tech-
nologies.22,24 The approach aims to ensure that all
technologies appropriate to the review are identified,
and this is facilitated by the use of multiple online
sources, including specialist media, health technology
assessment organizations, regulatory authorities,
research funders, subscription-only commercial
research and development databases, clinical trial
registries and professional and patient groups, in addi-
tion to bibliographic databases of published medical
literature and specialist journals. However, it is not
possible to claim that all possible technologies have
been identified as this is dependent on commercial,
media and academic reporting, though reassuringly
clinical experts did not know of any relevant technol-
ogies in development that had not already been iden-
tified. A particular limitation of horizon scanning
reviews is the restricted information on each technol-
ogy upon which to base inclusion/exclusion, filtra-
tion/prioritization and assessment decisions. It is
common for there to be limited publicly accessible
information and scientific data available for technol-
ogies in development or the early launch stage, and
we made no attempt to validate developers claims for
their products, all of which require further clinical
validation using patient-relevant outcomes and infor-
mation on costs prior to adoption.
The views of clinical experts and patients with
COPD provided essential insights into the place of
identified technologies in COPD management and the
acceptability of individual technologies to users. For
some technologies, there was disagreement as to their
potential impact, reflecting the individual’s particular
perspective, experience of similar developments and
local pathways of care. This was important, as we
sought consensus before labelling a technology as
particularly promising. Telehealth was a particular
source of disagreement in this review, with technolo-
gies receiving generally negative comments from
clinical experts, citing impracticality, the existing evi-
dence base and cost as a barrier to use, whereas
patients were broadly in favour of devices that
enabled them to self-monitor and communicate with
clinicians. Experts also noted the lack of evidence that
variables such as cough frequency or inhaler use were
associated with the risk of an acute exacerbation, and
that clinical trials of such systems typically measured
success in terms such as patient satisfaction, as
opposed to conventional clinical parameters, admis-
sions or healthcare utilization. In a field becoming
increasingly saturated with similar products, yet
experiencing little adoption by the NHS, it seems
unlikely that telehealth will become part of routine
COPD care until it is shown to improve patient out-
comes and a feasible cost-benefit balance is achieved.
Conclusion
This review identified several innovative technolo-
gies with the potential for impact in a disease with
a significant burden in the United Kingdom and
worldwide. The most promising technologies have
the potential to improve the early diagnosis of
COPD, facilitate patient self-monitoring and estab-
lish the cause of acute exacerbations, potentially at
the point of care. These technologies have the
potential to contribute to addressing key priorities
in the NHS Outcomes Framework, namely reduc-
ing premature deaths from respiratory disease,
enhancing the health-related quality of life of
patients with COPD and the quality of life of their
carers, ensuring people feel supported to manage
their condition and reducing unplanned admissions
and time in hospital.5 In addition, this review iden-
tified many technologies in the fields of telehealth
and wearable technologies that were considered to
be less promising, impractical or poorly directed.
This review enables the focus of future research
funding and NHS health technology assessment
activities to be appropriately targeted, thereby
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facilitating the adoption of technologies with the
potential to make a significant impact on NHS
COPD care and the quality of patients’ lives.
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